Fidelio completed the acquisition of a majority stake in Alphalyse.

Fidelio, a Swedish investment firm with offices in Stockholm and London, completed the acquisition of a majority stake in Alphalyse, a company that provides protein analysis services. Financial terms were not disclosed. “Demand for precise insights into HCP impurities is growing quickly as biologics pipelines continue to expand. Fidelio’s operational expertise and global network will allow us to increase our capacity and international footprint, ensuring developers and manufacturers have the data that regulators now expect from day one,” Thomas Kofoed, Alphalyse Co‑founder & CEO.